Feinburg, Judith E. and Hurwitz, Shelley and Cooper, David and Sattler, Fred R. and Macgregor, Rob Roy and Holland, Gary N. and Griffiths, Paul D. and Pollard, Richard and Youle, Michael and Gill, M. John and Holland, Fiona J and et al, . (1998) A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases, 177 (1). pp. 48-56. ISSN 0022-1899Full text not available from this repository.
Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.
|Journal or Publication Title:||Journal of Infectious Diseases|
|Additional Information:||© University of Chicago Press 1998|
|Subjects:||Q Science > QA Mathematics|
|Departments:||Faculty of Arts & Social Sciences > English & Creative Writing|
Faculty of Science and Technology > Lancaster Environment Centre
|Deposited On:||12 Nov 2008 16:53|
|Last Modified:||23 Oct 2016 00:02|
Actions (login required)